Skip to main content

Table 2 Association of cytoplasmic and nuclear Msx2 with clinicopathological parameters in 281 tumours on a TMAa

From: Homeobox transcription factor muscle segment homeobox 2 (Msx2) correlates with good prognosis in breast cancer patients and induces apoptosis in vitro

Variable

Cytoplasmic Msx2

Nuclear Msx2

 

Low Msx2

(n= 168)

High Msx2

(n= 113)

P value

Low Msx2

(n= 122)

High Msx2

(n= 159)

P value

Age

      

   Median (range)

66 (35-96)

64 (36-89)

 

65 (35-96)

65.5 (35-91)

 

   ≤50

23 (13.7)

14 (12.4)

0.752

19 (15.6)

18 (11.3)

0.296

   >50

145 (86.3)

99 (87.6)

 

103 (84.4)

141 (88.7)

 

Tumour size

      

   Median (range)

18 (0-100)

16 (1-100)

 

19 (0-100)

15.5 (1-100)

 

   ≤2 cm

105 (62.5)

75 (66.4)

0.507

74 (60.7)

106 (66.7)

0.298

   >2 cm

63 (37.5)

38 (33.6)

 

48 (39.3)

53 (33.3)

 

Histological type

      

   Ductal

115 (75.7)

75 (69.4)

0.157*

80 (72.7)

110 (73.3)

0.715*

   Lobular

19 (12.5)

22 (20.4)

 

19 (17.3)

22 (14.7)

 

   Tubular

9 (5.9)

8 (7.4)

 

5 (4.5)

12 (8)

 

   Medullary

5 3.3)

0

 

3 (2.7)

2 (1.3)

 

   Mucinous

4 (2.6)

3 (2.8)

 

3 (2.7)

4 (2.7)

 

   Unknown

16

5

 

12

9

 

Nodal status

      

   Negative

89 (59.3)

69 (69)

0.121

66 (61.1)

92 (64.8)

0.550

   Positive

61 (40.7)

31 (31)

 

42 (38.9)

50 (35.2)

 

   Unknown

18

13

 

14

17

 

Tumour grade

      

   I

34 (20.4)

35 (31)

0.012

20 (16.4)

49 (31)

0.015

   II

66 (39.5)

51 (45.1)

 

54 (44.3)

63 (39.9)

 

   III

67 (40.1)

27 (23.9)

 

48 (39.3)

46 (29.1)

 

   Unknown

1

0

 

0

1

 

ER status

      

   Negative

23 (14.1)

16 (14.7)

0.896

23 (19.3)

16 (10.5)

0.038

   Positive

140 (85.9)

93 (85.3)

 

96 (80.7)

137 (89.5)

 

   Unknown

5

4

 

3

6

 

PR status

      

   Negative

47 (36.4)

38 (40.9)

0.503

41 (40.6)

44 (36.4)

0.518

   Positive

82 (63.6)

55 (59.1)

 

60 (59.4)

77 (63.6)

 

   Unknown

39

20

 

21

38

 

Ki 67 (%)

      

   <10%

56 (34.1)

52 (48.6)

0.018

35 (30.2)

73 (47.1)

0.005

   >10%

108 (65.9)

55 (51.4)

 

81 (69.8)

82 (52.9)

 

   Unknown

4

6

 

6

4

 

VEGF (%)

      

   Low (0-2+)

92 (78)

77 (86.5)

0.116

76 (83.5)

93 (80.2)

0.537

   High (3)

26 (22)

12 (13.5)

 

15 (16.5)

23 (19.8)

 

   Unknown

50

24

 

31

43

 

Her2 (%)

      

   Low (0-2)

141 (89.2)

95 (92.2)

0.422

100 (89.3)

136 (91.3)

0.589

   High (3)

17 (10.8)

8 (7.8)

 

12 (10.7)

13 (8.7)

 

   Unknown

10

10

 

10

10

 

Cyclin D1 (%)

      

   Low (0-1%)

20 (12.5)

17 (15.7)

0.706

21 (17.9)

16 (10.6)

0.037

   Med (2-25%)

109 (68.1)

69 (63.9)

 

80 (68.4)

98 (64.9)

 

   High (>25%)

31 (19.4)

22 (20.4)

 

16 (13.7)

37 (24.5)

 

   Unknown

8

5

 

5

8

 
  1. aMsx2, muscle segment homeobox 2; ER, estrogen receptor; PR, progesterone receptor; Ki67, proliferation-related Ki-67 antigen; VEGF, vascular endothelial growth factor; Her2, human epidermal growth factor 2; *Fisher's exact test;, otherwise, χ2 test.